Clinical Trials Using Acetaminophen

Clinical trials are research studies that involve people. The clinical trials on this list are studying Acetaminophen. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-10 of 10
  • Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C / KEYNOTE-01C)

    The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) in combination with MK-5890 and MK-4830 in participants with advanced squamous or non-squamous NSCLC that have been previously treated with anti-PD-L1 therapy. This study is one of three pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01).
    Location: 3 locations

  • Autologous Lymphocyte Infusions after Chemotherapy and / or Radiation Therapy for Immune Reconstitution in Patients with Stage II-IVA Non-small Cell Lung Cancer or Esophageal Cancer

    This phase II trial studies the effect of autologous lymphocyte infusions after standard of care chemotherapy and / or radiation therapy on white blood cell count in patients with stage II-IVA non-small cell lung cancer or esophageal cancer. White blood cells fight infection and may kill tumor cells. Chemotherapy and radiation therapy may damage or destroy the white blood cells in blood. Apheresis is the procedure for collecting white blood cells. Giving white blood cells to patients after standard of care chemotherapy and radiation may help prevent infections and improve cancer treatment outcome. The goal of this trial is to learn if collecting patients’ white blood cells before standard of care chemotherapy and radiation therapy and then giving patients those white blood cells after chemotherapy and radiation therapy may help treat patients with non-small cell lung cancer or esophageal cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Chemotherapy and Cord Blood Transplant in Children and Young Adults with Hematologic Malignancies or Non-malignant Diseases

    This phase II trial studies the effect of chemotherapy and a cord blood transplant in children and young adults with hematologic malignancies or non-malignant diseases. Chemotherapy drugs, such as clofarabine, fludarabine, and busulfan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Before receiving stem cells, the standard process, called cytoreduction, is to receive high doses of chemotherapy. This helps to make room in the bone marrow for new blood stem cells to grow, helps prevent the body from rejecting the transplanted cells, and helps kill any cancer cells that are in the body. This is called a conditioning regimen. However, high doses of chemotherapy can have serious side effects. This study may help researchers learn whether combining the chemotherapy drugs clofarabine, fludarabine, and busulfan is a safe and effective way to reduce the side effects from receiving a conditioning regimen in children and young adults receiving cord blood transplants.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Durvalumab and Tremelimumab for the Treatment of Stage II-IIIB Non-small Cell Lung Cancer

    This clinical trial studies the effect of durvalumab and tremelimumab in treating patients with stage II-IIIB non-small cell lung cancer who have undergone surgical removal and completed after surgery treatment with or without radiation therapy and now have detectable tumor DNA in the blood. Durvalumab and tremelimumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Giving durvalumab and tremelimumab may help prevent cancer from returning (called cancer recurrence) when tumor DNA is detected in the blood.
    Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York

  • Assessing the Safety of Modified T Cells for Mesothelioma

    This phase I trial studies the effect and best dose of mesothelin-targeted chimeric antigen receptor (CAR)-T cells in treating patients with malignant pleural mesothelioma. T cells are a type of white blood cell that fight diseases like infections and cancer. Mesothelin (MSLN)-targeted CAR-T cell therapy, may activate the T cells to target and kill cancer cells that express mesothelin. MSLN-targeted CAR T cell therapy also includes an anti-PD1 component. Programmed cell death receptor 1 (PD1) is a protein that usually acts as a “brake” on the immune system. The anti-PD1 component blocks PD1, releasing the brakes and allowing T cells to target and destroy cancer cells. MSLN-targeted CAR T cell therapy may shrink or stabilize mesothelioma.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • MCARH109 CAR Modified T cells for the Treatment of Relapsed or Refractory Multiple Myeloma

    This phase I trial evaluates the side effects and best dose of MCARH109 chimeric antigen receptor (CAR) modified T cells in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Adding a gene (a small piece of DNA from a virus) to T cells may help the T cells recognize and kill cancer cells. These genetically modified cells are called chimeric antigen receptor T cells, and treatments made from them are called CAR-T therapies. MCARH109 is similar to other CAR-T therapies. Giving MCARH109 after chemotherapy may work to shrink or stop the growth of multiple myeloma.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Testing CAR-T Cell Therapy in Recurrent Epithelial Ovarian Cancer

    This phase I trial is to test the safety of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (CAR.B7-H3 T cells) in patients with ovarian cancer that has come back (recurrent). CAR.B7-H3 T cells combine two different ways the body fights cancer, antibodies and T cells. Antibodies are proteins that protect the body from foreign invaders like bacteria. Antibodies work by attaching to these bacteria or substances, which stops them from growing and causing bad effects. T cells, also called T lymphocytes, are special infection fighting blood cells that can kill viruses and other cells, including tumor cells. Antibodies and T cells have been used to treat patients with cancer. They both have shown promise, but neither alone has been able to cure most patients. This study will combine both T cells and antibodies to create a more effective treatment.
    Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

  • A Non-opioid Pain Control Regimen for Pain Management in Patients Undergoing Head and Neck Cancer Surgery

    This phase III trial studies how well a non-opioid pain control regimen administered before and during surgery works for pain management in patients undergoing head and neck cancer surgery. Opioids are a class of drugs that work in the brain to produce a variety of effects, including pain relief. In addition to controlling pain, opioids can make some people feel "high" and can be addictive. Acetaminophen, celecoxib, gabapentin, ketamine and lidocaine are non-opioid medications that when given before and during surgery, may improve post-surgery pain and / or decrease opioid consumption, which may relieve opioid related side effects and adverse symptoms, improve quality of life, and decrease the risk of chronic pain.
    Location: Case Comprehensive Cancer Center, Cleveland, Ohio

  • S1916 Digital Medicine Program for Pain Control in Cancer Patients

    This is a feasibility study to assess the use of a Digital Medicine Program (consisting of an FDA-approved ingestible sensor co-encapsulated with oxycodone / acetaminophen (5 mg / 325 mg), a small wearable patch, and a mobile application) in cancer patients with metastatic disease experiencing uncontrolled pain.
    Location: See Clinical

  • Biomarker Testing in Studying APAP-CYS Concentrations in Primary or Secondary Liver Cancer Patients with Non-acetaminophen Induced Liver Injury

    This phase IV trial studies APAP-CYS concentrations in primary or secondary liver cancer patients with non-acetaminophen induced liver injury after taking therapeutic doses of acetaminophen. This research may help doctors in the future better understand protein adduct concentrations in patient’s blood.
    Location: University of Colorado Hospital, Aurora, Colorado